Compass Therapeutics

Founded in 2014 by CEO Thomas Schuetz and CSO Piotr Bobrowicz and based in Massachusetts, US, Compass Therapeutics, Inc. is a biotechnology company that focuses on the development of therapeutic antibodies for the treatment of cancer and other tumor-immune synapses., Compass Therapeutics, Inc. will operate as a public company. In November 2021, Compass Therapeutics, Inc.50 per share on the NASDAQ. It trades on NASDAQ under the ticker symbol CMPX. In May 2021, Compass Therapeutics, Inc., a private biotechnology oncology company, in a stock for stock transaction. The products in the company's pipeline include CTX-009, CTX-471, CTX-8371. CTX-009 is a bispecific antibody that simultaneously targets Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A). CTX-009 has completed Phase 1 dose-escalation and expansion study, and a Phase 1b in combination with chemotherapy is ongoing. CTX-009 has shown clinical efficacy as a monotherapy in severely pre-treated patients who have progressed following prior VEGF, EGFR, HER2, and PD1/L1-targeted treatments. CTX-471 is a fully human agonistic antibody of CD137. CTX-471 is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. CTX-8371 is a bispecific antibody that targets both the programmed death receptor (PD-1) and the programmed death ligand-receptor (PD-L1) on immune and cancer cells, respectively. CTX-8371 is currently undergoing IND-enabling preclinical development. Compass Therapeutics, Inc.

1. Series A

   Jul 11, 2018

   Amount

   $49M

   Investors

   Locked

2. Series A

   Jun 30, 2015

   Amount

   Undisclosed

   Investors

   Locked